Tracked deals
19
19 tracked deals across 2020-2026.
Billerica, Massachusetts, United States
Bruker is a leading analytical instrumentation company providing technological solutions for analytical tasks across research and industrial production. Its systems are used to ensure quality and process reliability, with offerings spanning scientific instruments, analytical measurement, and diagnostic/life-science solutions.
Tracked deals
19
19 tracked deals across 2020-2026.
Recent pace
2
2 tracked deals announced in the last 12 months.
Deal mix
Buyout
19 buyout
Last 6 years
Supporting Data
Showing the 12 most recent of 19 tracked deals for Bruker Corporation.
Bruker acquired the DISQVER clinical metagenomics sequencing platform from Noscendo GmbH to expand its infection diagnostics portfolio. DISQVER enables whole-genome sequencing-based pathogen detection directly from blood samples and remains available for research use only while Bruker advances regulatory registration for diagnostic applications.
Bruker Corporation acquired the remaining 60% ownership stake in TOFWERK AG, consolidating its ownership to 100%. The acquisition brings TOFWERK's compact, ultra-fast time-of-flight mass spectrometry technology and ~130 employees into Bruker's portfolio to expand capabilities and address applied markets such as air quality, semiconductor cleanroom monitoring, and food/flavors testing.
Bruker Corporation has acquired biocrates life sciences ag, an Innsbruck, Austria-based leader in mass-spectrometry-based quantitative metabolomics. The deal adds biocrates' metabolomics kits, assays, software and contract research services to Bruker's multiomics strategy, expanding Bruker's MS-based metabolomics and integrated multiomics capabilities. Financial terms were not disclosed.
Bruker Corporation announced a majority investment in RECIPE Chemicals + Instruments GmbH, a Munich-based provider of mass spectrometry‑based in vitro diagnostic assay kits for therapeutic drug monitoring. The deal (financial terms undisclosed) brings RECIPE's ClinMASS kits into Bruker's portfolio and creates a strategic collaboration to introduce high‑throughput, chromatography‑free ClinDART workflows on Bruker's EVOQ‑DART TQ⁺ platform.
Bruker Corporation has acquired Dynamic Biosensors GmbH, a Munich-based developer of single-cell interaction cytometry and biosensor instruments, to strengthen Bruker’s biosensors portfolio. The deal combines Dynamic Biosensors’ heliXcyto and heliX+ technologies with Bruker’s high-throughput SPR systems to expand capabilities and product offerings for drug discovery and biopharma research; financial terms were not disclosed.
Bruker Corporation has acquired substantially all assets of NanoString Technologies, Inc. through a court-supervised Chapter 11 asset sale for approximately $392.6 million in cash plus assumption of certain liabilities. The deal, announced April 2024 and closed in late April/early May 2024, brings NanoString's spatial biology and gene-expression product lines into Bruker to preserve customer access, product development, and jobs while expanding Bruker's life‑science instrumentation capabilities.
Bruker Corporation has acquired Spectral Instruments Imaging LLC, a Tucson-based maker of preclinical in‑vivo optical imaging systems, to broaden Bruker BioSpin's preclinical imaging portfolio. Financial terms were not disclosed; SII generated over $10 million in revenue in 2023 and will expand Bruker's capabilities in bioluminescence, fluorescence and X‑ray preclinical imaging.
Bruker Corporation has acquired Tornado Spectral Systems Inc., a Mississauga, Ontario-based maker of process Raman instruments, to expand Bruker’s biopharma Process Analytical Technology (PAT) product portfolio. Financial terms were not disclosed; Tornado’s HTVS-enabled Raman analyzers and probes will be integrated into Bruker’s spectroscopy and biopharma offerings to enhance process monitoring and quality control capabilities.
Bruker Corporation has acquired Nion, a Kirkland, Washington developer and manufacturer of high-end scanning transmission electron microscopes (STEM), including the UltraSTEM line and advanced EELS technology. The acquisition strengthens Bruker's materials science instrumentation portfolio and provides capabilities for electron diffraction crystallography; Nion reported approximately $8 million in revenue in 2023. Financial terms were not disclosed.
PAI Partners has entered into an agreement with Bruker Corporation to sell ELITech Group, a global manufacturer of in-vitro diagnostics (IVD) instruments and reagents. The deal is subject to regulatory and customary closing conditions and includes a put option for the sale. Under PAI’s ownership since 2017, ELITech pursued R&D investments, next-generation molecular diagnostics systems, and strategic partnerships.
Bruker Corporation has signed a definitive agreement to acquire PhenomeX Inc in an all-cash transaction valued at approximately $108 million equity value ($1.00 per share). The deal is expected to close in the fourth quarter of 2023, subject to customary closing conditions, after which PhenomeX will merge into a wholly owned Bruker subsidiary.
Bruker Corporation has closed the acquisition of ZONTAL Inc., a provider of a GxP-compliant life-sciences data platform, to strengthen Bruker BioSpin's Integrated Data Solutions (IDS) software portfolio. The deal (terms not disclosed) will integrate ZONTAL's vendor-agnostic laboratory and process data management capabilities with Bruker's Mestrelab, Arxspan and Optimal offerings to accelerate digital laboratory transformation for biopharma and life-science customers; ZONTAL expected 2023 revenues of greater than $5 million.
Turn tracked acquisition activity into an outreach-ready buyer list.